Effect of Mirabegron for the ureteral stent

Not Applicable

Recruiting

Conditions: Diseases of The genitoruinary system

Registration Number: KCT0002599

Lead Sponsor: Korea University Ansan Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients to be undergone double J stent indwelling after flexible or rigid ureteroscopic stone removal.
1. =20 years
2. Undergoing unilateral retrograde double-J (DJ) stent (6Fr) placement planned for 5-28 days indwelling (only after ureteroscopic procedure, retrograde intrarenal surgery)

Exclusion Criteria

1. After percutaneous nephrolithotomy, open or laparoscopic ureterolithotomy
2. Presence of ureteral stone
3. Renal insufficiency (serum Cr > 1.7)
4. Febrile UTI (fever > 38°, evidence of urinary infection)
5. Pregnancy or breast feeding
6. Solitary kidney
7. Hypersensitivity to mirabegron
8. Current use of any alpha-blocker, calcium-channel blocker, corticosteroid, Anti-muscarinic agents (within 4 weeks)
9. Moderate or severe cardiovascular or cerebrovascular disease
10. Hepatic dysfunction (>2 x normal LFT)
11. Prior history of pelvic surgery or irradiation
12. Prior history of TURBT or prostate surgery
13. Significant active medical illness which in the opinion of the investigator would preclude protocol treatment
14. Genetic disorder such as Galatose intolerance, Lapp Lactase deficiency, Glucose-Galactose malabsorption

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SSQ urinary symptom score (Body pain score)

Secondary Outcome Measures

Name	Time	Method
USSQ general health score;USSQ work performance score;IPSS (International prostate symptom score)/ QoL score;additional analgesics use;Post voiding residual urine volume